BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

• Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality was reported over the 30 month acoramidis treatment period - Acoramidis was well-tolerated, with no safety signals of potential clinical concern identified - These results support local regulatory submission in Japan - The findings from this study build upon positive results from BridgeBio's global ATTRibute-CM P ...